Abiopharma

(90% Positive) Elanco Animal Health Incorporated (ELAN) Reports Q1 2026 Financial Results

(90% Positive) Esperion Therapeutics Inc (ESPR) Provides Update on results for Esperion’s history

Profound Surpasses 2025 TULSA-PRO® Installed Base Goal

(99% Positive) Oncology Institute Inc (TOI) Reports Q1 2026 Financial Results

(99% Neutral) TransMedics Group Inc. (TMDX) Announces Business Combination

MDxHealth Reports Preliminary Fourth Quarter and Full Year 2025 Revenues, Issues 2026 Revenue Guidance, and Amends Earnout Terms with Exact Sciences

(70% Positive) Galecto Inc. (GLTO) Announces Enrollment Update for contained Due to Geopolitical Situation, Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

Atara Biotherapeutics Provides Regulatory and Business Update onEBVALLO™ (tabelecleucel)

KORU Medical Systems Reports Preliminary Q4 and Full Year 2025 Results; Achieves Record Revenue and Full Year Positive Operating Cash Flow

Cabaletta Bio Announces 2026 Strategic Priorities

Director Schuetz Thomas J. 🔴 sold 46.8K shares of Compass Therapeutics, Inc. (CMPX) at $5.35 Transaction Date: Jan 09, 2026 | Filing ID: 000205

Erasca Announces Promising Early Clinical Data for ERAS-0015 and 2026-2027 Milestones

Prestige Consumer Healthcare Announces Fiscal 2026 Third Quarter Earnings Results Date and Participation in the ICR Conference

CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2025 Financial Results and Issues Fiscal 2026 Guidance

Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)